Stock events for Palisade Bio, Inc. (PALI)
Over the past six months, Palisade Bio's stock has experienced significant events and volatility. In October 2025, the company closed an upsized public offering, raising approximately $138 million to support the Phase 2 clinical development program for PALI-2108 in Ulcerative Colitis. In August 2025, Palisade Bio reported positive topline results from its Phase 1b open-label cohort in patients with moderate-to-severe UC, demonstrating a 100% clinical response. Analyst ratings for PALI have been mixed but generally lean positive, with a consensus rating of "Moderate Buy" as of February 2026. The stock has shown considerable volatility, with its share price fluctuating over the past three months and a year-to-date decrease of 30.6%.
Demand Seasonality affecting Palisade Bio, Inc.’s stock price
As a clinical-stage biopharmaceutical company, Palisade Bio's revenue generation is not tied to seasonal consumer purchasing patterns but rather to milestones in its drug development pipeline. Traditional demand seasonality for its products and services is not applicable at this stage.
Overview of Palisade Bio, Inc.’s business
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. Their primary product candidate is PALI-2108, a prodrug PDE4 inhibitor in Phase 1a/b clinical trials for ulcerative colitis and Phase 1a trials for fibrostenotic Crohn's disease. The company is also researching PALI-1908 and developing oral therapies for gastrointestinal complications, including LB1148.
PALI’s Geographic footprint
Palisade Bio is headquartered in Carlsbad, California, United States. Its shares are listed on the Nasdaq Capital Market in the US and on the Deutsche Boerse AG and Frankfurt Stock Exchange in Germany, indicating a primary operational focus in the United States with a presence in European financial markets.
PALI Corporate Image Assessment
Palisade Bio's brand reputation has been influenced by positive clinical developments and some financial concerns. The company received a boost from positive topline results in its Phase 1b clinical trial for PALI-2108 in ulcerative colitis. Analyst coverage generally reflects a "Moderate Buy" consensus, and the strategic equity investment from the Crohn's & Colitis Foundation's IBD Ventures Program is a positive endorsement. However, some analysts have downgraded the stock, and concerns have been raised regarding the company's financial challenges, including a lack of commercial infrastructure and the potential need for additional capital.
Ownership
Palisade Bio's ownership structure is characterized by a significant institutional presence, with institutional investors collectively owning approximately 54.05% to 56.40% of the company's stock. Major institutional shareholders include Perceptive Advisors LLC, Commodore Capital LP, and Janus Henderson Group PLC. Individual insider ownership is relatively low, with approximately 0.04% of the stock held by insiders.
